Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma
Rani, Sweta, Gately, Kathy, Crown, John, O'Byrne, Ken, & O'Driscoll, Lorraine (2013) Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma. Cancer Biology and Therapy, 14(12), pp. 1104-1112.
Early diagnosis and the ability to predict the most relevant treatment option for individuals is essential to improve clinical outcomes for non-small cell lung cancer (NSCLC) patients. Adenocarcinoma (ADC), a subtype of NSCLC, is the single biggest cancer killer and therefore an urgent need to identify minimally invasive biomarkers to enable early diagnosis. Recent studies, by ourselves and others, indicate that circulating miRNA s have potential as biomarkers. Here we applied global profiling approaches in serum from patients with ADC of the lung to explore if miRNA s have potential as diagnostic biomarkers. This study involved RNA isolation from 80 sera specimens including those from ADC patients (equal numbers of stages 1, 2, 3, and 4) and age- and gender-matched controls (n = 40 each). Six hundred and sixty-seven miRNA s were co-analyzed in these specimens using TaqMan low density arrays and qPCR validation using individual miRNA s. Overall, approximately 390 and 370 miRNA s were detected in ADC and control sera, respectively. A group of 6 miRNA s, miR-30c-1* (AU C = 0.74; P < 0.002), miR-616(AU C = 0.71; P = 0.001), miR-146b-3p (AU C = 0.82; P < 0.0001), miR-566 (AU C = 0.80; P < 0.0001), miR-550 (AU C = 0.72; P = 0.0006), and miR-939 (AU C = 0.82; P < 0.0001) was found to be present at substantially higher levels in ADC compared with control sera. Conversely, miR-339-5p and miR-656 were detected at substantially lower levels in ADC sera (co-analysis resulting in AU C = 0.6; P = 0.02). Differences in miRNA profile identified support circulating miRNA s having potential as diagnostic biomarkers for ADC. More extensive studies of ADC and control serum specimens are warranted to independently validate the potential clinical relevance of these miRNA s as minimally invasive biomarkers for ADC.
Impact and interest:
Citation counts are sourced monthly from and citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
|Item Type:||Journal Article|
|Keywords:||Adenocarcinoma, Biomarker, Circulating, Lung cancer, Micro-RNAs (miRNAs), Minimally invasive, ROC curve, microRNA, microRNA 103, microRNA 146b 3p, microRNA 16, microRNA 192, microRNA 30c 1, microRNA 339 5p, microRNA 451, microRNA 550, microRNA 566, microRNA 616, microRNA 939, tumor marker, unclassified drug, untranslated RNA, age, area under the curve, article, cancer patient, controlled study, density, disease severity, down regulation, female, gender, human, lung adenocarcinoma, major clinical study, male, polymerase chain reaction, receiver operating characteristic, RNA isolation, upregulation|
|Subjects:||Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000) > ONCOLOGY AND CARCINOGENESIS (111200)|
|Divisions:||Current > Schools > School of Biomedical Sciences
Current > QUT Faculties and Divisions > Faculty of Health
Current > Institutes > Institute of Health and Biomedical Innovation
|Copyright Owner:||Copyright 2013 Landes Bioscience|
|Deposited On:||25 Feb 2014 04:01|
|Last Modified:||26 Feb 2014 00:08|
Repository Staff Only: item control page